Is NCT03666000 recruiting in Tampa, FL?

Yes, NCT03666000 is currently recruiting participants at its Tampa, FL location. This non-hodgkin lymphoma clinical trial is actively enrolling qualified participants.

How do I join the non-hodgkin lymphoma clinical trial in Tampa?

To join this clinical trial in Tampa, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Tampa clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Non-Hodgkin Lymphoma Clinical Trial in Tampa, FL

Who Can Participate

Inclusion Criteria

Criteria for B-ALL: • Participant has confirmed unequivocal r/r CD19+ B-ALL. Criteria for NHL and CLL/SLL: • Participant has unequivocal aggressive CD19+ r/r B-cell NHL that is confirmed by tumor biopsy tissue from last relapse after CD19-directed therapy. For Phase 1 Dose Escalation:

Diffuse large B-cell lymphoma (DLBCL) including Richter's transformation

Follicular lymphoma (FL) including Grade 3 or transformed FL

High-grade B-cell lymphoma (HGBCL)

Primary mediastinal lymphoma For Phase 1b Dose Expansion (CAR T-relapsed cohort):

DLBCL not otherwise specified (NOS)

DLBCL transformed from the following indolent lymphoma subtypes (FL, Marginal Zone lymphoma \[MZL\], and Waldenstrom's Macroglobulinemia \[WM\])

Other large B-cell lymphoma (LBCL) subtypes may be enrolled with approval from the Medical Monitor.

Participants previously treated with CD19-directed autologous CAR T therapies have received no more than 2 lines of therapy after administration of their previous CAR T product.

For the expansion CAR T-relapsed cohort only: Participants must have received autologous CD19-directed CAR T therapy and demonstrated clinical response to the treatment at Day 28 or later, followed by relapse or progression. For Phase 1b dose expansion (CAR T-naive cohort):

DLBCL transformed from the following indolent lymphoma subtypes (FL, MZL, and WM)

FL (Grade 1-3a)

MZL that is fluorodeoxyglucose (FDG)-avid on positron emission tomography (PET) scan

Primary central nervous system (CNS) lymphoma (PCNSL)

Other LBCL subtypes may be enrolled with approval from the Medical Monitor.

Participant must have received at least 1-2 prior lines of therapy, depending on histological subtype but no more than 7 systemic lines of anti-cancer therapy. Criteria for both B-ALL, NHL, and CLL/SLL:

Eastern Cooperative Oncology Group performance status score of 0 or 1.

An estimated life expectancy of at least 12 weeks according to the investigator's judgment.

Seronegative for human immunodeficiency virus antibody.

Participant has adequate bone marrow, renal, hepatic, pulmonary, and cardiac function. Key

Exclusion Criteria

Criteria for B-ALL: • Burkitt cell (L3 ALL) or mixed-lineage acute leukemia. Criteria for NHL:

Requirement for urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression.

Active hemolytic anemia. Criteria for B-ALL and NHL:

No active CNS disease, excluding PCNSL

History of another primary malignancy

Any form of primary immunodeficiency (for example, severe combined immunodeficiency disease).

History of hepatitis B or hepatitis C currently receiving ongoing antiviral therapy. Any known uncontrolled cardiovascular disease at the time of Screening that, in the investigator's opinion, renders the participant ineligible

History of hypertension crisis or hypertensive encephalopathy within 3 months prior to Screening.

History of severe immediate hypersensitivity reaction to any of the agents used in this study.

Presence of a CNS disorder that, in the opinion of the investigator, renders the participant ineligible for treatment.

History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome, or any other known bone marrow failure syndrome.

Active uncontrolled autoimmune disease requiring active immunosuppression at the time of Screening (excluding participants needing steroids for physiologic replacement).

Participant has received stem cell transplant within 90 days before Screening.

Participant has active graft-versus-host disease (GvHD) symptoms.

Participant has received a systemic biologic agent for treatment of the disease under study within 28 days of LD, other systemic anti-cancer therapy within 10 days or 5 half-lives (whichever is shorter) of LD, and no pulse steroid for disease control within 3 days of LD.

Radiotherapy within 4 weeks before Screening.

Presence of pleural/peritoneal/pericardial catheter, as well as permeant biliary and ureteral stents (does not apply to intravenous lines).

Participant has received live vaccine within 4 weeks before Screening. Note: Non-live virus vaccines are not excluded.

Participant has received CD19-directed therapy other than autologous CD19-directed CAR T therapy within 90 days of the anticipated start date of LD. Additional criteria apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tampa?

Yes, this clinical trial (NCT03666000) has an active research site in Tampa, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-Hodgkin Lymphoma Treatment Options in Tampa, FL

If you're searching for non-hodgkin lymphoma treatment options in Tampa, FL, this clinical trial (NCT03666000) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tampa research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-hodgkin lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-hodgkin lymphoma clinical trials near you to find additional studies recruiting in your area.

Non-Hodgkin Lymphoma Clinical Trial in Tampa, FL

Expert Care in Tampa

IRB Approved

No-Cost Care

Apply for This Tampa Location

Why Participate?

Simple Process

About This Non-Hodgkin Lymphoma Study in Tampa